Ablation of a site of progression with stereotactic body radiation therapy extends sunitinib treatment from 14 to 22 months

Journal of Clinical Oncology

Volumn 31, Issue 23, 2013, Pages

  Straka, Christopher ^a   Kim, D W Nathan ^a   Timmerman, Robert D ^a   Pedrosa, Ivan ^a   Jacobs, Corbin ^a   Brugarolas, James ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; HEMOGLOBIN; SUNITINIB; TEMSIROLIMUS;

ADRENAL METASTASIS; AGED; ARTICLE; BONE METASTASIS; CANCER GROWTH; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SIZE; CANCER SURGERY; CARDIOVASCULAR RISK; CASE REPORT; DIABETES MELLITUS; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPISTAXIS; FATIGUE; FOLLOW UP; HUMAN; HYPERTENSION; KIDNEY TUMOR; LYMPHADENOPATHY; MALE; MEDICAL HISTORY; MULTIMODALITY CANCER THERAPY; NEPHRECTOMY; PERCUTANEOUS VERTEBROPLASTY; PRIORITY JOURNAL; STEREOTACTIC BODY RADIATION THERAPY; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION;

ABLATION TECHNIQUES; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; PYRROLES; RADIOSURGERY;

EID: 84890521589     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.47.7455     Document Type: Article

References (28)

1. Motzer RJ, Russo P: Systemic therapy for renal cell carcinoma. J Urol 163:408-417, 2000
2. McDermott DF, Regan MM, Clark JI, et al: Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 23:133-141, 2005
3. Negrier S, Escudier B, Lasset C, et al: Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. N Engl J Med 338:1272-1278, 1998
4. Mendel DB, Laird AD, Xin X, et al: In vivo antitumor activity of su11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors. Clin Cancer Res 9:327-337, 2003
5. Brugarolas J: Renal-cell carcinoma: Molecular pathways and therapies. N Engl J Med 356:185-187, 2007
6. Motzer RJ, Hutson TE, Tomczak P, et al: Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27:3584-3590, 2009
7. Motzer RJ, Hutson TE, Tomczak P, et al: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124, 2007
8. Rini BI, Atkins MB: Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol 10:992-1000, 2009
9. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247, 2009
10. Fidler IJ: Tumor heterogeneity and the biology of cancer invasion and metastasis. Cancer Res 38:2651-2660, 1978
11. Loeb LA: Human cancers express mutator phenotypes: Origin, consequences and targeting. Nat Rev Cancer 11:450-457, 2011
12. Turner NC, Reis-Filho JS: Genetic heterogeneity and cancer drug resistance. Lancet Oncol 13:e178-e185, 2012
13. Gerlinger M, Rowan AJ, Horswell S, et al: Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366:883-892, 2012
14. Alt AL, Boorjian SA, Lohse CM, et al: Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer 117:2873-2882, 2011
15. Blanco AI, Teh BS, Amato RJ: Role of radiation therapy in the management of renal cell cancer. Cancers 3:4010-4023, 2011
16. Sinisa Stanic WGR, Boike TP, Timmerman RD: Is renal cell carcinoma really radioresistant? Experience with stereotactic body radiotherapy in patients for primary and metastatic renal cell carcinoma. Kidney Cancer J 9:35-40, 2011
17. Ranck MC, Golden DW, Corbin KS, et al: Stereotactic body radiotherapy for the treatment of oligometastatic renal cell carcinoma. Am J Clin Oncol doi:10.1097/COC.0b013e31825d52b2
18. Svedman C, Sandström P, Pisa P, et al: A prospective phase II trial of using extracranial stereotactic radiotherapy in primary and metastatic renal cell carcinoma. Acta Oncol 45:870-875, 2006
19. Svedman C, Karlsson K, Rutkowska E, et al: Stereotactic body radiotherapy of primary and metastatic renal lesions for patients with only one functioning kidney. Acta Oncol 47:1578-1583, 2008
20. Salama JK, Hasselle MD, Chmura SJ, et al: Stereotactic body radiotherapy for multisite extracranial oligometastases. Cancer 118:2962-2970, 2012
21. Mazeron R, Anderson B, Supiot S, et al: Current state of knowledge regarding the use of antiangiogenic agents with radiation therapy. Cancer Treat Rev 37:476-486, 2011
22. Staehler M, Haseke N, Stadler T, et al: Feasibility and effects of high-dose hypofractionated radiation therapy and simultaneous multi-kinase inhibition with sunitinib in progressive metastatic renal cell cancer. Urol Oncol 30:290-293, 2012
23. Kao J, Packer S, Vu HL, et al: Phase 1 study of concurrent sunitinib and image-guided radiotherapy followed by maintenance sunitinib for patients with oligometastases. Cancer 115:3571-3580, 2009
24. Tong CCL, Ko EC, Sung MW, et al: Phase II trial of concurrent sunitinib and image-guided radiotherapy for oligometastases. PLoS ONE 7:e36979, 2012
25. Inoue T, Kinoshita H, Komai Y, et al: Two cases of gastrointestinal perforation after radiotherapy in patients receiving tyrosine kinase inhibitor for advanced renal cell carcinoma. World J Surg Oncol 10:167, 2012
26. Peters NA, Richel DJ, Verhoeff JJ, et al: Bowel perforation after radiotherapy in a patient receiving sorafenib. J Clin Oncol 26:2405-2406, 2008
27. Ott PA, Hamilton A, Min C, et al: A phase II trial of sorafenib in metastatic melanoma with tissue correlates. PLoS ONE 5:e15588, 2010
28. Kennedy GD, Heise CP: Radiation colitis and proctitis. Clin Colon Rectal Surg 20:64-72, 2007